This is a snippet of the transcript, sign up to read more.
Currently, the estimates are that around 40% of clinics in North America belong to one of these networks. The networks have typically bought the bigger clinics, so more than half of the cycles are performed within a network. In Europe, it's probably less than that, around 30%.
This is a snippet of the transcript, sign up to read more.
In some markets like the UK, the vast majority of private cycles are performed within one of these networks. In the UK, it's probably 65% of cycles performed within a clinic owned by a network with private equity involvement. In other places like Germany, it's much less. Spain is relatively high, so it's a fragmented picture in Europe.
This is a snippet of the transcript, sign up to read more.
Equipment falls under capex, so it goes into a different bracket. It gets messier now because many services like genomic services and embryo options are added in. If you take the core business of any of these companies, which includes basic consumables like dishes, pipettes, media, and cryopreservation, you're probably looking at maybe $250 to $300 per cycle. In the US, a cycle can cost anywhere between $10,000 and $20,000. Europe is a bit more fragmented, but you could take an average of around $4,000 to $8,000 per cycle, probably closer to $8,000 in the UK.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.